247 related articles for article (PubMed ID: 20870280)
1. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
2. Changes in tumor blood flow as measured by Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) may predict activity of single agent bevacizumab in recurrent epithelial ovarian (EOC) and primary peritoneal cancer (PPC) patients: an exploratory analysis of a Gynecologic Oncology Group Phase II study.
Chase DM; Sill MW; Monk BJ; Chambers MD; Darcy KM; Han ES; Buening BJ; Sorosky JI; Fruehauf JP; Burger RA
Gynecol Oncol; 2012 Sep; 126(3):375-80. PubMed ID: 22683587
[TBL] [Abstract][Full Text] [Related]
3. Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Bais C; Mueller B; Brady MF; Mannel RS; Burger RA; Wei W; Marien KM; Kockx MM; Husain A; Birrer MJ;
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059426
[TBL] [Abstract][Full Text] [Related]
4. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study.
Burger RA; Sill MW; Monk BJ; Greer BE; Sorosky JI
J Clin Oncol; 2007 Nov; 25(33):5165-71. PubMed ID: 18024863
[TBL] [Abstract][Full Text] [Related]
6. Randomized phase III trial of tamoxifen versus thalidomide in women with biochemical-recurrent-only epithelial ovarian, fallopian tube or primary peritoneal carcinoma after a complete response to first-line platinum/taxane chemotherapy with an evaluation of serum vascular endothelial growth factor (VEGF): A Gynecologic Oncology Group Study.
Hurteau JA; Brady MF; Darcy KM; McGuire WP; Edmonds P; Pearl ML; Ivanov I; Tewari KS; Mannel RS; Zanotti K; Benbrook DM
Gynecol Oncol; 2010 Dec; 119(3):444-50. PubMed ID: 20846715
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors.
Tao X; Sood AK; Deavers MT; Schmeler KM; Nick AM; Coleman RL; Milojevic L; Gershenson DM; Brown J
Gynecol Oncol; 2009 Sep; 114(3):431-6. PubMed ID: 19524286
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of serum CA-125 levels in patients with persistent or recurrent epithelial ovarian cancer or peritoneal cancer treated with bevacizumab on a Gynecologic Oncology Group phase II trial.
Randall LM; Sill MW; Burger RA; Monk BJ; Buening B; Sorosky JI
Gynecol Oncol; 2012 Mar; 124(3):563-8. PubMed ID: 22138229
[TBL] [Abstract][Full Text] [Related]
11. A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies.
Usha L; Sill MW; Darcy KM; Benbrook DM; Hurteau JA; Michelin DP; Mannel RS; Hanjani P; De Geest K; Godwin AK
Gynecol Oncol; 2011 Jun; 121(3):455-61. PubMed ID: 21414654
[TBL] [Abstract][Full Text] [Related]
12. Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study.
Secord AA; Darcy KM; Hutson A; Lee PS; Havrilesky LJ; Grace LA; Berchuck A;
Gynecol Oncol; 2007 Jul; 106(1):221-32. PubMed ID: 17481705
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Aghajanian C; Sill MW; Darcy KM; Greer B; McMeekin DS; Rose PG; Rotmensch J; Barnes MN; Hanjani P; Leslie KK
J Clin Oncol; 2011 Jun; 29(16):2259-65. PubMed ID: 21537039
[TBL] [Abstract][Full Text] [Related]
14. Markers of angiogenesis in high-risk, early-stage cervical cancer: A Gynecologic Oncology Group study.
Randall LM; Monk BJ; Darcy KM; Tian C; Burger RA; Liao SY; Peters WA; Stock RJ; Fruehauf JP
Gynecol Oncol; 2009 Mar; 112(3):583-9. PubMed ID: 19110305
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
[TBL] [Abstract][Full Text] [Related]
16. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer.
Slaughter KN; Thai T; Penaroza S; Benbrook DM; Thavathiru E; Ding K; Nelson T; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Apr; 133(1):11-5. PubMed ID: 24680585
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.
Behbakht K; Sill MW; Darcy KM; Rubin SC; Mannel RS; Waggoner S; Schilder RJ; Cai KQ; Godwin AK; Alpaugh RK
Gynecol Oncol; 2011 Oct; 123(1):19-26. PubMed ID: 21752435
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of thalidomide in patients with refractory leiomyosarcoma of the uterus and correlation with biomarkers of angiogenesis: a gynecologic oncology group study.
McMeekin DS; Sill MW; Darcy KM; Stearns-Kurosawa DJ; Webster K; Waggoner S; Benbrook D
Gynecol Oncol; 2007 Sep; 106(3):596-603. PubMed ID: 17597196
[TBL] [Abstract][Full Text] [Related]
20. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection.
Collinson F; Hutchinson M; Craven RA; Cairns DA; Zougman A; Wind TC; Gahir N; Messenger MP; Jackson S; Thompson D; Adusei C; Ledermann JA; Hall G; Jayson GC; Selby PJ; Banks RE
Clin Cancer Res; 2013 Sep; 19(18):5227-39. PubMed ID: 23935036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
